• Line management of 2 direct reports & matrix management of additional 7 individuals contributing to a translational platform.• Leadership of a patient derived 3D Tumor Spheroid platform studying Tumor Infiltrating Lymphocytes (TIL) for up to 3 simultaneous projects. • Responsible for data summation, presentation & effective communication with Project Leads.• Moderator for various departmental meetings including SPARK! for novel science & literature review.• Initiated… Show more • Line management of 2 direct reports & matrix management of additional 7 individuals contributing to a translational platform.• Leadership of a patient derived 3D Tumor Spheroid platform studying Tumor Infiltrating Lymphocytes (TIL) for up to 3 simultaneous projects. • Responsible for data summation, presentation & effective communication with Project Leads.• Moderator for various departmental meetings including SPARK! for novel science & literature review.• Initiated development of Translational assays (Coculture & Organoid models) to elucidate the effects of GSK assets on Hematologic malignancies. Show less

ImmunoOncology DPU (Jan 2013 to 2019)•Design of Multi-color Flow Cytometry Panels to study both tumor & immune cell response to various agents.•Monocyte isolation & Dendtric Cell Differentiation assessing the impact of lead compounds via flow cytometry & MSD cytokine assays.•Development of a Dendritc/Tumor Cell co-culture assay system to study the effects of drug treated tumor cells on Dendritic cell differentiation.Cancer Epitope DPU in Oncology (Mar 2012 to Dec… Show more ImmunoOncology DPU (Jan 2013 to 2019)•Design of Multi-color Flow Cytometry Panels to study both tumor & immune cell response to various agents.•Monocyte isolation & Dendtric Cell Differentiation assessing the impact of lead compounds via flow cytometry & MSD cytokine assays.•Development of a Dendritc/Tumor Cell co-culture assay system to study the effects of drug treated tumor cells on Dendritic cell differentiation.Cancer Epitope DPU in Oncology (Mar 2012 to Dec 2012)•Studied receptor internalization & recycling for an antibody-drug conjugate via Flow Cytometry techniques.•Supported the identification of relevant Biomarkers to evaluate apoptosis & cell death in the clinic.•Established & optimized an ADCC assay generating key Go/No Go decisions for the project.Novel Targets BDU in Biopharma (May 2011 to Feb 2012)•FMAT & Flow Cytometry analysis of a group of cell lines to detect expression of receptors of interest.•ELISA method development followed by usage in routine screening of cell media for expression of protein of interest.•in vivo methods including orbital bleeds, tail vein injections & tracking of body weights. Show less

Immunoassay Core Group in Pre-Clinical.• Performed Mouse Potency ELISA studies in a GMP environment to rapidly clear a large backlog of samples supporting a high profile project.• Made substantial improvements to sample inventory systems, assay templates, electronic notebook entries, and the approved protocol.• Responsible for Lab Safety compliance, equipment, reagent, and sample inventories, & training personnel as Lab Manager.• Authored both SOP and AP documents.• ELISA… Show more Immunoassay Core Group in Pre-Clinical.• Performed Mouse Potency ELISA studies in a GMP environment to rapidly clear a large backlog of samples supporting a high profile project.• Made substantial improvements to sample inventory systems, assay templates, electronic notebook entries, and the approved protocol.• Responsible for Lab Safety compliance, equipment, reagent, and sample inventories, & training personnel as Lab Manager.• Authored both SOP and AP documents.• ELISA method development.• Developed methods employing the Gyros platform for automated immunoassay technology. Show less

•Managed the development, validation, and conversion of assays to a high throughput format employing automated liquid handling systems.•Developed Mammalian Two-Hybrid Screens assessing protein/protein interaction.•Played an integral role on the sFRP-1 Antagonist Discovery Team seeking to identify inhibitors of this WNT pathway regulator as potential Osteoporosis therapies. Independently managed all in vivo studies for the Team including study design, implementation, and analysis… Show more •Managed the development, validation, and conversion of assays to a high throughput format employing automated liquid handling systems.•Developed Mammalian Two-Hybrid Screens assessing protein/protein interaction.•Played an integral role on the sFRP-1 Antagonist Discovery Team seeking to identify inhibitors of this WNT pathway regulator as potential Osteoporosis therapies. Independently managed all in vivo studies for the Team including study design, implementation, and analysis including pQCT bone densitometry, RNA isolation, & Taqman.•Performed a series of studies assessing the utility of various Biomarkers using ELISA’s and RIA’s.•Developed stable Ror2 over-expressing cell lines.•Performed transient transfection experiments to elucidate Ror2’s involvement in the WNT pathway and Osteoporosis. •Characterization of several KO or transgenic mouse models.•Performed Western Blotting to determine protein regulation in cell fractions. Show less

•Participated in binding studies to identify and characterize Estrogen Receptor Beta selective compounds. •Performed secondary cell based assays to assess compound’s effects on target genes via Taqman assay.•Conducted reporter luciferase studies for a Estrogen Receptor compound screen.•Executed in vivo assays to assess the uterotrophic effects of compounds.•Validated an in vivo dextran sodium sulfate model of colitis & employed histological techniques > cryo & paraffin… Show more •Participated in binding studies to identify and characterize Estrogen Receptor Beta selective compounds. •Performed secondary cell based assays to assess compound’s effects on target genes via Taqman assay.•Conducted reporter luciferase studies for a Estrogen Receptor compound screen.•Executed in vivo assays to assess the uterotrophic effects of compounds.•Validated an in vivo dextran sodium sulfate model of colitis & employed histological techniques > cryo & paraffin sectioning, in situ hybridization & staining.•Assisted in cloning of relevant genes for project Show less

•NIDDM research focusing on the effects of PTPases on Insulin signal transduction. Characterized the activity of lead compounds in various enzymatic, cellular, and in vivo assays.•Performed a recombinant enzyme assay examining compounds ability to inhibit PTP1B and increase Insulin Receptor phosphorylation.•Gluconeogenesis, glycogenolysis, and glucose transport assays

•Harvested primary cells via rat liver perfusions. •Performed in vivo assays to assess the ability of test compounds to normalize blood glucose in various diabetic models including db/db & ob/ob mouse and Zucker rats.•Protein immunoprecipitation, cell fractionation, and Western blotting